{"id":943444,"date":"2026-03-11T07:32:28","date_gmt":"2026-03-11T11:32:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/"},"modified":"2026-03-11T07:32:28","modified_gmt":"2026-03-11T11:32:28","slug":"reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/","title":{"rendered":"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026"},"content":{"rendered":"

<\/p>\n

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026<\/b><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–Kirby McInerney LLP<\/a> reminds Corcept Therapeutics Incorporated (\u201cCorcept\u201d or the \u201cCompany\u201d) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.<\/p>\n

\nIf you purchased or otherwise acquired Corcept securities, have information, or would like to learn more, please contact Lauren Molinaro<\/a> of Kirby McInerney LLP by email at investigations@kmllp.com<\/a>, or fill out the form below, to discuss your rights or interests.<\/p>\n

\n[CONTACT THE FIRM IF YOU SUFFERED A LOSS<\/a>]<\/p>\n

What Is The Lawsuit About?<\/b><\/p>\n

\nThe lawsuit has been filed on behalf of investors who purchased securities during the period of October 31, 2024 through December 30, 2025, inclusive (\u201cthe Class Period\u201d). The lawsuit alleges that the Company represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were \u201cpowerful support\u201d for the New Drug Application (\u201cNDA\u201d) that Corcept submitted to the U.S. Food and Drug Administration (\u201cFDA\u201d) for this indication. The Company also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the Class Period, Corcept repeatedly told investors that \u201crelacorilant is approaching approval.\u201d In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the relacorilant NDA and, as a result, there was a known material risk that Corcept\u2019s relacorilant NDA would not be approved.<\/p>\n

\nOn December 31, 2025, Corcept revealed that the FDA had issued a Complete Response Letter (\u201cCRL\u201d) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had \u201cconcluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.\u201d On this news, the price of Corcept shares declined by $35.40 per share, or approximately 50.4%, from $70.20 per share on December 30, 2025 to close at $34.80 on December 31, 2025.<\/p>\n

\nOn January 30, 2026, after the end of the Class Period, the FDA published a redacted copy of the CRL. The CRL detailed the FDA\u2019s concerns with the relacorilant NDA, including concerns that the clinical studies that were submitted as part of the NDA were not sufficient evidence of relacorilant\u2019s efficacy for the proposed indication. The CRL also noted that, during pre-submission meetings, the FDA informed Corcept \u201con several occasions\u201d of its \u201cconcerns about the adequacy of the clinical development program,\u201d and had warned the Company \u201cto expect significant review issues,\u201d if it submitted the application. On this news, the price of Corcept shares declined by $4.74 per share, or approximately 10.6%, from $44.61 per share on January 29, 2026 to close at $39.87 on January 30, 2026.<\/p>\n

\n[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION<\/a>]<\/p>\n

What Should I Do?<\/b><\/p>\n

\nIf you purchased or otherwise acquired Corcept securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro<\/a> of Kirby McInerney LLP<\/a> by email at investigations@kmllp.com<\/a>, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.<\/p>\n

\n[WHAT IS A SECURITIES CLASS ACTION?<\/a>]<\/p>\n

Kirby McInerney LLP<\/a> is a New York-based plaintiffs\u2019 law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm\u2019s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP\u2019s website<\/a>.<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260310628815\/en\/<\/a><\/span><\/p>\n

\nKirby McInerney LLP
\n
Lauren Molinaro, Esq.
\n
212-699-1171
\n
https:\/\/www.kmllp.com
\n<\/a>
https:\/\/securitiesleadplaintiff.com\/
\n<\/a>
investigations@kmllp.com<\/a><\/p>\n

KEYWORDS:<\/b> New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 NEW YORK–(BUSINESS WIRE)–Kirby McInerney LLP reminds Corcept Therapeutics Incorporated (\u201cCorcept\u201d or the \u201cCompany\u201d) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. If you purchased or otherwise acquired Corcept securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill … <\/p>\n

Continue reading “REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-943444","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nREMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 NEW YORK–(BUSINESS WIRE)–Kirby McInerney LLP reminds Corcept Therapeutics Incorporated (\u201cCorcept\u201d or the \u201cCompany\u201d) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. If you purchased or otherwise acquired Corcept securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill … Continue reading "REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T11:32:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026\",\"datePublished\":\"2026-03-11T11:32:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/\"},\"wordCount\":698,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/\",\"name\":\"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-03-11T11:32:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/","og_locale":"en_US","og_type":"article","og_title":"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 - Market Newsdesk","og_description":"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 NEW YORK–(BUSINESS WIRE)–Kirby McInerney LLP reminds Corcept Therapeutics Incorporated (\u201cCorcept\u201d or the \u201cCompany\u201d) (NASDAQ:CORT) investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. If you purchased or otherwise acquired Corcept securities, have information, or would like to learn more, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill … Continue reading \"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-11T11:32:28+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026","datePublished":"2026-03-11T11:32:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/"},"wordCount":698,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/","name":"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-03-11T11:32:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260310628815r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/reminder-corcept-therapeutics-incorporated-investors-with-significant-losses-must-act-by-april-21-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=943444"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/943444\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=943444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=943444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=943444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}